The combination therapy of PEG-IFN alpha 2b, Ribavirin and Telaprevir for the patients with chronic hepatitis C:the study for treatment duration by response guided therapy and prediction of efficacy by gene analysis in Japan.

The combination therapy of PEG-IFN alpha 2b, Ribavirin and Telaprevir for the patients with chronic hepatitis C:the study for treatment duration by response guided therapy and prediction of efficacy by gene analysis in Japan. - The response guided therapy of PEG-IFN alpha 2b, Ribavirin and Telaprevir for the patients with chronic hepatitis C

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018971

Enrollment

500

Registered

2015-10-02

Start date

2012-09-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis C

Interventions

Seiection according to Rapid Virological Response treatment trem

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: chronic hepatitis C genotype1b and high viral load (Real time PCR; over 5.0Log IU/mL)

Exclusion criteria

Exclusion criteria: 1. patients contraindication for telaprevir 2) patients with rush by telaprevir 3) patients who used contraindication drugs with telaprevir 4) pregnacy 5) pregnacy for partener 6) partner can not understand contraception 7) allergy for RBV 8) sevre heart disease 9) salasemia 10) sevre renal disease 11) mental desease 12) sevre liver disease 13) AIH 14) contraindication for PEG-IFN-2b 15) allergy for vaccine 16) shosaikoto user 17) plick test positive 18) a. Hb>12g/dl b. nuet>1,500/mm3 c. platetlet>100,000/mm3 19) past use of telaprevir 20) active infecious desisease 21) cancer 22) contraindication by doctor in charge

Design outcomes

Primary

Measure	Time frame
SVR rate	—

Countries

Japan

Contacts

Public ContactKazuhiko Hayashi

Nagoya university Gastroenterolgy and Hepatology

kazuh@med.nagoya-u.ac.jp052-741-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026